Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-11-14 |
2024-09 |
-0.75 |
N/A |
N/A |
N/A |
2024-08-12 |
2024-06 |
-0.64 |
-0.58 |
0.06 |
9.38% |
2024-05-14 |
2024-03 |
-0.78 |
-0.67 |
0.11 |
14.10% |
2024-05-14 |
2024-03 |
-0.78 |
N/A |
N/A |
N/A |
2024-03-26 |
2023-12 |
-0.56 |
-0.92 |
-0.36 |
-64.29% |
2024-03-26 |
2023-12 |
-0.56 |
N/A |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-09-12 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-09 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-05-15 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-03-09 |
Maxim Group |
Upgrade |
|
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-06-19 |
DUEY MARC |
Director |
210.53K |
Stock Award(Grant) |
2024-03-27 |
GILAD OREN PH.D. |
Chief Executive Officer |
333.30K |
Stock Award(Grant) |
2024-06-19 |
GRISSINGER MICHAEL J. |
Director |
1.84K |
Stock Award(Grant) |
2024-03-27 |
HAMILL JOHN P |
Chief Financial Officer |
18.87K |
Stock Award(Grant) |
2024-06-19 |
HENNEMAN JOHN BELL III |
Director |
9.18K |
Stock Award(Grant) |
2024-04-30 |
MIRZA NADEEM Q. |
Officer |
6.73K |
Stock Award(Grant) |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
AIGH Capital Management LLC |
349.30K |
1.10M |
9.35% |
2023-06-29 |
Sio Capital Management, LLC |
280.00K |
882.00K |
7.49% |
2023-06-29 |
Walleye Capital LLC |
93.63K |
294.93K |
2.51% |
2023-06-29 |
Worth Venture Partners, Llc |
87.17K |
274.58K |
2.33% |
2023-06-29 |
Geode Capital Management, LLC |
23.59K |
74.31K |
0.63% |
2023-06-29 |
Morgan Stanley |
15.28K |
48.14K |
0.41% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Extended Market Index Fund |
9.38K |
29.53K |
0.25% |
2023-05-30 |
Fidelity Extended Market Index Fund |
5.11K |
19.68K |
0.14% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
4.99K |
15.72K |
0.13% |
2023-05-30 |
Fidelity Series Total Market Index Fund |
1.10K |
4.24K |
0.03% |
2023-06-29 |
Vanguard Institutional Index-Inst Total Stock Market Ind |
1.14K |
3.58K |
0.03% |
2023-05-30 |
Fidelity Total Market Index Fund |
833.00 |
3.21K |
0.02% |
Split |
Date |
1 : 20 |
2023-02-13 |
1 : 1000 |
2018-12-27 |